Breaking News

Parexel Announces CEO Transition

Jamie Macdonald will retire and transition his role as CEO to the company’s COO and Growth Officer Peyton Howell.

Author Image

By: Charlie Sternberg

Associate Editor

Parexel, a clinical research organization (CRO) providing the full range of Phase I to IV clinical development services, has announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the company’s Chief Operating and Growth Officer Peyton Howell effective May 15, 2024.   Howell, who joined Parexel in 2018 as Chief Commercial and Strategy Officer, will be appointed to the company’s Board of Directors May 15. Macdonald will continue on the Board throu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters